Levi & Korsinsky Investigates Fairness of Revance Therapeutics Acquisition by Crown Laboratories
New York, NY – In a recent press release, Levi & Korsinsky, LLP, a leading securities law firm, announced the commencement of an investigation into the fairness of the acquisition of Revance Therapeutics Inc. (RVNC) by Crown Laboratories, Inc. (Crown). The investigation focuses on whether the acquisition price adequately reflects the value of Revance Therapeutics stock purchased prior to August 11, 2024.
Background of the Acquisition
Revance Therapeutics, a biotechnology company, focuses on the development of novel and sustainable medicines, primarily in the therapeutic areas of dermatology and aesthetics. Crown Laboratories, a specialty pharmaceutical company, announced on August 11, 2024, that it had entered into a definitive agreement to acquire Revance in a transaction valued at approximately $2.1 billion.
Investigation Details
Levi & Korsinsky is investigating potential breaches of fiduciary duty, a failure to disclose material information, and other violations of state and federal securities laws by the Revance Board of Directors. The investigation follows a decline in Revance’s stock price prior to the acquisition announcement, which raises concerns about whether the acquisition price adequately compensates Revance shareholders.
Impact on Shareholders
If you own Revance Therapeutics stock purchased prior to August 11, 2024, and wish to learn more about this investigation, please contact Levi & Korsinsky, LLP. You may be entitled to recover damages if it is determined that the investigation uncovers evidence of wrongdoing. The investigation is ongoing, and Levi & Korsinsky will provide updates as more information becomes available.
Impact on the World
The outcome of this investigation could have significant implications for the biotech industry and the broader investment community. It may influence future mergers and acquisitions and could lead to increased scrutiny of similar transactions. Additionally, it may encourage more shareholders to seek legal representation when they believe the value of their investments has been undervalued.
Conclusion
Levi & Korsinsky’s investigation into the acquisition of Revance Therapeutics by Crown Laboratories raises important questions about the fairness of the transaction and the potential impact on shareholders. If you own Revance Therapeutics stock purchased prior to August 11, 2024, and are concerned about the potential implications of this investigation, we encourage you to contact Levi & Korsinsky, LLP for more information. The investigation is ongoing, and updates will be provided as new information becomes available.
- Levi & Korsinsky, LLP, a leading securities law firm, has commenced an investigation into the fairness of the acquisition of Revance Therapeutics Inc. (RVNC) by Crown Laboratories, Inc. (Crown).
- The investigation focuses on potential breaches of fiduciary duty, failure to disclose material information, and other violations of state and federal securities laws.
- Shareholders who own Revance Therapeutics stock purchased prior to August 11, 2024, may be entitled to recover damages if wrongdoing is uncovered.
- The outcome of this investigation could have significant implications for the biotech industry and the broader investment community.
- For more information, contact Levi & Korsinsky, LLP.
